10-Q: Iris Acquisition Corp Reports Q2 2024 Results Amidst Business Combination Challenges

Iris Acquisition Corp reported a net loss for the second quarter of 2024 and is facing challenges in completing its business combination with Liminatus Pharma.

Summary

• Iris Acquisition Corp, a blank check company, reported a net loss of $534,854 for the three months ended June 30, 2024, and a net loss of $1,393,085 for the six months ended June 30, 2024.
• The company's operating expenses included $642,082 in formation and operating costs for the quarter and $1,363,836 for the six-month period.
• The company experienced a loss on the change in fair value of warrants of $100,089 for the six-month period.
• The company had $339,203 in cash in its operating bank account as of June 30, 2024, with a working capital deficit of approximately $6,059,539.
• The company is facing a deadline of September 9, 2024, to complete its business combination, and the recent termination of a key licensing agreement with Targeted Diagnostics & Therapeutics, Inc. has introduced further uncertainty.
• The company has amended its business combination agreement multiple times, extending the outside date to September 3, 2024.
• The company has also extended the date to complete the business combination to September 9, 2024, and is seeking a further extension to December 31, 2024.
• The company has a promissory note with Liminatus Pharma LLC with a principal amount of up to $3,500,000, with $2,318,500 outstanding as of June 30, 2024.
• The company has a deferred underwriting discount of $9,660,000, which may be reduced to $8,000,000 upon completion of the business combination with Liminatus.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, a high risk of liquidation, and the termination of a key agreement, leading to a negative sentiment.

Positives

• The company has secured a promissory note with Liminatus Pharma LLC for up to $3,500,000, providing additional funding.
• The company is actively seeking an extension to complete the business combination, indicating a commitment to the transaction.

Negatives

• The company reported a net loss of $534,854 for the three months ended June 30, 2024, and a net loss of $1,393,085 for the six months ended June 30, 2024.
• The company has a significant working capital deficit of approximately $6,059,539.
• The termination of a key licensing agreement for Liminatus Pharma has introduced significant uncertainty.
• The company's ability to continue as a going concern is in doubt if the business combination is not completed by September 9, 2024.
• The company has identified material weaknesses in its internal controls over financial reporting.

Risks

• The company may not be able to complete its business combination by the deadline of September 9, 2024, potentially leading to liquidation.
• The termination of the licensing agreement with Targeted Diagnostics & Therapeutics, Inc. has significantly impacted the business combination.
• The company has a significant working capital deficit and may need additional financing.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company is subject to a 1% excise tax on share redemptions, which could reduce the value of its Class A common stock.
• The company's ability to complete the business combination is dependent on the PIPE investment and other financing, which are not guaranteed.

Future Outlook

The company is seeking an extension to complete its business combination by December 31, 2024, due to the recent termination of a key licensing agreement. The company's ability to continue as a going concern is dependent on completing the business combination.

Management Comments

• Management has determined that if the Company is unable to complete a Business Combination by September 9, 2024, then the Company will cease all operations except for the purpose of liquidating.
• Management has determined that the Company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the Company's ability to continue as a going concern.

Industry Context

The document reflects the challenges faced by many SPACs in completing their initial business combinations, particularly given the current market conditions and regulatory scrutiny. The termination of the licensing agreement highlights the risks associated with early-stage biotech companies, which are often the targets of SPAC mergers.

Comparison to Industry Standards

• The financial performance of Iris Acquisition Corp is below average compared to other SPACs that have successfully completed their business combinations.
• The company's high operating costs and significant working capital deficit are concerning compared to industry benchmarks.
• The multiple extensions and amendments to the business combination agreement are not uncommon in the SPAC market, but the termination of the licensing agreement is a significant setback.
• The company's reliance on related party loans and the potential for liquidation are also not uncommon in the SPAC market, but they highlight the risks associated with these types of transactions.
• The company's internal control weaknesses are a significant concern and are not typical of well-managed SPACs.

Management Changes

Related Party Transactions

• The company has a promissory note with its Sponsor, Iris Acquisition Holdings LLC, with a total outstanding balance of $1,453,720 as of June 30, 2024.
• The company has an administrative support agreement with Arrow Capital Management LLC, paying $10,000 per month.
• The Sponsor has agreed to loan the company funds for extension payments.

Stakeholder Impact

• Shareholders face a high risk of losing their investment if the business combination is not completed and the company is liquidated.
• Employees of the company and Liminatus Pharma face uncertainty regarding their future employment.
• Creditors of the company may not be fully repaid if the company is liquidated.
• The company's suppliers and vendors may be impacted by the company's financial difficulties.

Next Steps

• The company will seek stockholder approval to extend the date to complete the business combination to December 31, 2024.
• The company will file a post-effective amendment to ParentCo's Registration Statement on Form S-4 to disclose the change to Liminatus's business.
• The company will reschedule a previously scheduled meeting of stockholders to a later date.
• The company will continue to pursue the business combination with Liminatus Pharma, LLC.

Key Dates

Keywords

SPAC, Business Combination, Liminatus Pharma, Merger, Acquisition, Financial Results, Warrants, Redemption, Promissory Note, Going Concern, Excise Tax